Moderna Inc. has announced the voluntary withdrawal of its Biologics License Application $(BLA.AU)$ for its combination vaccine against influenza and COVID-19, mRNA-1083, in consultation with the U.S. Food and Drug Administration (FDA). The company plans to resubmit the application later this year, once efficacy data from the ongoing Phase 3 trial of its seasonal influenza vaccine, mRNA-1010, become available. This decision reflects an ongoing regulatory review process, with interim data expected this summer. No grant or funding information was specified in the announcement.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.